Clinical Trials Logo

Ascites, Malignant clinical trials

View clinical trials related to Ascites, Malignant.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06046963 Recruiting - Gastric Cancer Clinical Trials

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion as First-line Treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with malignant ascites

NCT ID: NCT05726747 Recruiting - Ascites Hepatic Clinical Trials

QOL and Sarcopenia in Patients With Ascites

Start date: May 23, 2023
Phase:
Study type: Observational

Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more robust. One primary objective of this study is to study changes in quality in life in a prospective fashion using newer general and ascites-specific quality of life survey instruments specific to benign and malignant etiologies. Sarcopenia is a condition that is prevalent in cancer and cirrhosis. Current data is retrospective and associative, evaluating heterogeneous patient populations at different stages within the timeline of refractory ascites. The other primary objective of this study is to study sarcopenia in a prospective fashion and to understand its kinetics once a patient develops refractory ascites. Prospectively-obtained measures of deterioration in patient-reported outcomes and in muscle mass will form the basis for the next stage of investigation of interventions to mitigate these declines.

NCT ID: NCT05461430 Recruiting - Pancreatic Cancer Clinical Trials

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

TraveraRTGx
Start date: July 15, 2022
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.